MLYS
Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. (MLYS) has 17 SEC Form 4 filings (94 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 16, 2026.
The most active filer is Chief Medical Officer Rodman David Malcom with 16 filings. Insiders have net sold $10.3M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Jon Congleton
- Employees:51
- HQ:Radnor, PA, US
- IPO:2023-02-10
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$36.6M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$2.3B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Executive Officer | Sale | 10,700 | $291K | Jul 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,058 | $388K | Jul 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,349 | $169K | Jul 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 2,171 | $66K | Jul 10 | SEC ↗ | |
| Chief Executive Officer | Sale | 75,000 | $2.0M | Jun 30 | SEC ↗ | |
Warren EricFirst filing | Chief Commercial Officer | Sale | 104,124 | $2.7M | Jun 30 | SEC ↗ |
| Chief Medical Officer | Sale | 9,890 | $235K | Jun 18 | SEC ↗ | |
| Chief Medical Officer | Sale | 4,584 | $115K | Jun 18 | SEC ↗ | |
Karydas DaphneFirst filing | Director | Sale | 3,000 | $75K | Jun 18 | SEC ↗ |
| Chief Medical Officer | Sale | 2,171 | $65K | May 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,348 | $186K | May 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,056 | $402K | May 14 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,058 | $373K | Apr 15 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,348 | $176K | Apr 15 | SEC ↗ | |
Congleton JonFirst in 5 months | Chief Executive Officer | Sale | 75,000 | $2.0M | Apr 2 | SEC ↗ |
| Chief Medical Officer | Sale | 6,348 | $174K | Mar 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,058 | $369K | Mar 16 | SEC ↗ | |
| Chief Medical Officer | Sale | 6,349 | $184K | Feb 13 | SEC ↗ | |
| Chief Medical Officer | Sale | 14,055 | $386K | Feb 13 | SEC ↗ | |
Rodman David MalcomFirst filing | Chief Medical Officer | Sale | 70,037 | $2.5M | Jan 6 | SEC ↗ |
Rodman David MalcomFirst filing | Chief Medical Officer | Sale | 192,715 | $6.7M | Jan 6 | SEC ↗ |
Levy Adam ScottFirst in 4 months | CFO and Secretary | Sale | 119,524 | $5.4M | Nov 13 | SEC ↗ |
Gold Alexander MFirst filing | Director | Sale | 15,000 | $660K | Nov 13 | SEC ↗ |
Gold Alexander MFirst filing | Director | Sale | 6,933 | $324K | Nov 13 | SEC ↗ |
Gold Alexander MFirst filing | Director | Sale | 12,742 | $593K | Nov 13 | SEC ↗ |
Congleton JonFirst filing | Chief Executive Officer | Sale | 200,000 | $9.1M | Nov 13 | SEC ↗ |
Levy Adam ScottFirst filing | CFO and Secretary | Sale | 12,946 | $182K | Jul 30 | SEC ↗ |
Levy Adam ScottFirst filing | CFO and Secretary | Sale | 807 | $11K | Jul 30 | SEC ↗ |
Levy Adam ScottFirst filing | CFO and Secretary | Sale | 59,925 | $884K | Jul 30 | SEC ↗ |
Related companies
Mineralys Therapeutics, Inc. is in the Healthcare sector.